TUMOR ANGIOGENESIS

Angiogenesis was first identified as an important process in tumor survival and sustenance in the 1980's, but the therapeutic potential of anti-angiogenic agents was only realized and implemented into clinical practice in early 2000. It is well recognized that tumors selectively recruit vasculature which serves to provide a survival advantage, while also permitting escape from natural defense mechanisms. Research into modification of this process of neovascularization, using anti-angiogenic agents, has shown that tumor cell death can be significantly accelerated, especially in combination with cytotoxic chemotherapy. We discuss the research that has been conducted in elucidating the process of angiogenesis in the tumor micro-environment, and the possible pharmacological interventions to achieve clinical benefit with tumor responses.